A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
2期
已完成
NCT01797523
| 适应症 | Endometrial Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | M.D. Anderson Cancer Center |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 62 人 |
|---|
| 干预（药物） | Metformin, Letrozole, Everolimus |
|---|
| 开始日期 | 2013年10月7日 |
|---|
| 完成日期 | 2026年2月4日 |
|---|
| 结果公布日 | 2026年7月30日 |
|---|
摘要
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied. Everolimus is designed to block a protein inside cancer cells that is involved in cancer growth. Letrozole is designed to block a protein from making estrogen. This may interfere with the growth of cancer cells. Metformin is commonly used to control blood sugar levels in patients with diabetes. It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells.
Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.
93 months · Participants
| Rad-Let-Met | 27 Participants |
|---|
| Rad-Let-Met | 15 Participants |
|---|
| Rad-Let-Met | 12 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。